Transcranial photobiomodulation increases intrinsic brain activity within irradiated areas in early Alzheimer's disease: Potential link with cerebral metabolism

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: These data were presented at the ACNP Annual Meeting, Tampa, FL, December 2023. Dr. Katherine Collins serves as a consultant for Cronos Clinical Consulting, Inc., and Relmada Therapeutics. In the last 10 years, Dr. Dan Iosifescu has served as a consultant for Alkermes, Allergan, Angelini, Autobahn, Axsome, Biogen, Boehringer Ingelheim, the Centers for Psychiatric Excellence, Clexio, Delix, Jazz, Lundbeck, Neumora, Otsuka, Precision Neuroscience, Relmada, Sage Therapeutics, and Sunovion. Dr. Dan Iosifescu has received grant support (paid to his institutions) from Alkermes, AstraZeneca, BrainsWay, LiteCure, NeoSync, Otsuka, Roche, and Shire. Dr. Paolo Cassano consulted for Janssen Research and Development and for Niraxx Light Therapeutics Inc. Dr. Paolo Cassano was funded by PhotoThera Inc, LiteCure LLC and Cerebral Sciences Inc to conduct studies on transcranial photobiomodulation. Dr. Paolo Cassano is a co-founder, shareholder and board director of Niraxx Inc. Dr. Paolo Cassano has filed several patents related to the use of near-infrared light in psychiatry. All other authors report no biomedical financial interests or potential conflicts of interest.